Y Nakamura7, K Namikawa2, K Yoshino3, S Yoshikawa4, H Uchi5, K Goto6, Y Nakamura7, S Fukushima8, Y Kiniwa9, T Takenouchi10, H Uhara11, T Kawai12, N Hatta13, T Funakoshi14, Y Teramoto15, A Otsuka16, H Doi17, D Ogata18, S Matsushita19, T Isei20, T Hayashi21, Y Shibayama22, N Yamazaki2. 1. Department of Skin Oncology/Dermatology, Comprehensive Cancer Center, Saitama Medical University International Medical Center, Saitama, Japan. Electronic address: ynakamur@saitama-med.ac.jp. 2. Department of Dermatologic Oncology, National Cancer Center Hospital, Tokyo, Japan. 3. Department of Dermatologic Oncology, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Tokyo, Japan. 4. Department of Dermatology, Shizuoka Cancer Center, Shizuoka, Japan. 5. Department of Dermatology, Kyushu University, Fukuoka, Japan. 6. Department of Dermatology, Nagoya University, Nagoya, Japan. 7. Department of Dermatology, University of Tsukuba, Tsukuba, Japan. 8. Department of Dermatology and Plastic Surgery, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan. 9. Department of Dermatology, Shinshu University, Matsumoto, Japan. 10. Department of Dermatology, Niigata Cancer Center, Niigata, Japan. 11. Department of Dermatology, Sapporo Medical University, Sapporo, Japan. 12. Department of Dermatology, University of Tokyo, Tokyo, Japan. 13. Department of Dermatology, Toyama Prefectural Central Hospital, Toyama, Japan. 14. Department of Dermatology, Keio University, Tokyo, Japan. 15. Department of Skin Oncology/Dermatology, Comprehensive Cancer Center, Saitama Medical University International Medical Center, Saitama, Japan. 16. Department of Dermatology, Kyoto University, Kyoto, Japan. 17. Department of Dermatology, Asahikawa Medical University, Asahikawa, Japan. 18. Department of Dermatology, Saitama Medical University, Saitama, Japan. 19. Department of Dermato-Oncology/Dermatology, National Hospital Organization Kagoshima Medical Center, Kagoshima, Japan. 20. Department of Dermatological Oncology, Osaka International Cancer Institute, Osaka, Japan. 21. Plastic and Reconstructive Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan. 22. Department of Dermatology, Fukuoka University, Fukuoka, Japan.
Abstract
BACKGROUND: Acral melanoma (AM) is an epidemiologically and molecularly distinct entity that is underrepresented in clinical trials on immunotherapy in melanoma. We aimed to analyze the efficacy of anti-programmed cell death 1 (anti-PD-1) antibodies in advanced AM. PATIENTS AND METHODS: We retrospectively evaluated unresectable stage III or stage IV AM patients treated with an anti-PD-1 antibody in any line at 21 Japanese institutions between 2014 and 2018. The clinicobiologic characteristics, objective response rate (ORR, RECIST), survival estimated using Kaplan-Meier analysis, and toxicity (Common Terminology Criteria for Adverse Events 4.0.) were analyzed to estimate the efficacy of the anti-PD-1 antibodies. RESULTS: In total, 193 patients (nail apparatus, 70; palm and sole, 123) were included in the study. Anti-PD-1 antibody was used as first-line therapy in 143 patients (74.1%). Baseline lactate dehydrogenase (LDH) was within the normal concentration in 102 patients (52.8%). The ORR of all patients was 16.6% (complete response, 3.1%; partial response, 13.5%), and the median overall survival (OS) was 18.1 months. Normal LDH concentrations showed a significantly stronger association with better OS than abnormal concentrations (median OS 24.9 versus 10.7 months; P < 0.001). Although baseline characteristics were similar between the nail apparatus and the palm and sole groups, ORR was significantly lower in the nail apparatus group [6/70 patients (8.6%) versus 26/123 patients (21.1%); P = 0.026]. Moreover, the median OS in this group was significantly poorer (12.8 versus 22.3 months; P = 0.03). CONCLUSIONS: Anti-PD-1 antibodies have limited efficacy in AM patients. Notably, patients with nail apparatus melanoma had poorer response and survival, making nail apparatus melanoma a strong candidate for further research on the efficacy of novel combination therapies with immune checkpoint inhibitors.
BACKGROUND:Acral melanoma (AM) is an epidemiologically and molecularly distinct entity that is underrepresented in clinical trials on immunotherapy in melanoma. We aimed to analyze the efficacy of anti-programmed cell death 1 (anti-PD-1) antibodies in advanced AM. PATIENTS AND METHODS: We retrospectively evaluated unresectable stage III or stage IV AM patients treated with an anti-PD-1 antibody in any line at 21 Japanese institutions between 2014 and 2018. The clinicobiologic characteristics, objective response rate (ORR, RECIST), survival estimated using Kaplan-Meier analysis, and toxicity (Common Terminology Criteria for Adverse Events 4.0.) were analyzed to estimate the efficacy of the anti-PD-1 antibodies. RESULTS: In total, 193 patients (nail apparatus, 70; palm and sole, 123) were included in the study. Anti-PD-1 antibody was used as first-line therapy in 143 patients (74.1%). Baseline lactate dehydrogenase (LDH) was within the normal concentration in 102 patients (52.8%). The ORR of all patients was 16.6% (complete response, 3.1%; partial response, 13.5%), and the median overall survival (OS) was 18.1 months. Normal LDH concentrations showed a significantly stronger association with better OS than abnormal concentrations (median OS 24.9 versus 10.7 months; P < 0.001). Although baseline characteristics were similar between the nail apparatus and the palm and sole groups, ORR was significantly lower in the nail apparatus group [6/70 patients (8.6%) versus 26/123 patients (21.1%); P = 0.026]. Moreover, the median OS in this group was significantly poorer (12.8 versus 22.3 months; P = 0.03). CONCLUSIONS: Anti-PD-1 antibodies have limited efficacy in AM patients. Notably, patients with nail apparatus melanoma had poorer response and survival, making nail apparatus melanoma a strong candidate for further research on the efficacy of novel combination therapies with immune checkpoint inhibitors.
Authors: Dai Ogata; Lauren E Haydu; Isabella C Glitza; Sapna P Patel; Hussein A Tawbi; Jennifer L McQuade; Adi Diab; Suhendan Ekmekcioglu; Michael K Wong; Michael A Davies; Rodabe N Amaria Journal: Cancer Med Date: 2021-03-08 Impact factor: 4.452
Authors: Avani M Kolla; Gerardo A Vitiello; Erica B Friedman; James Sun; Aishwarya Potdar; Hala Daou; Norma E Farrow; Clara R Farley; John T Vetto; Dale Han; Marvi Tariq; Georgia M Beasley; Carlo M Contreras; Michael Lowe; Jonathan S Zager; Iman Osman; Russell S Berman; Tracey N Liebman; Jennifer A Stein; Ann Y Lee Journal: Cancer Control Date: 2021 Jan-Dec Impact factor: 3.302
Authors: Xue Bai; Jie Dai; Caili Li; Chuanliang Cui; Lili Mao; Xiaoting Wei; Xinan Sheng; Zhihong Chi; Xieqiao Yan; Bixia Tang; Bin Lian; Xuan Wang; Li Zhou; Siming Li; Yan Kong; Zhonghui Qi; Huayan Xu; Rong Duan; Jun Guo; Lu Si Journal: Front Oncol Date: 2021-05-20 Impact factor: 6.244